Luis Garcia-Mayol, MD
Nephrology · Coral Gables, FLNPI 1003816463
Payments from drug & device makers
Across 762 payments — averaging $527.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$193K
- Akebia Therapeutics Inc$84K
- Vifor Pharma, Inc.$61K
- AstraZeneca$53K
- Mallinckrodt Hospital Products Inc.$5K
- Amgen$1K
- plus $5K from 23 others
What the payments were for
- Consulting fees$4,2005%
- Speaking & faculty fees$48,85864%
- Travel & lodging$7,0589%
- Food & beverage$16,19021%
- Education$3470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 123 | $193,435 |
| Akebia Therapeutics Inc | 88 | $83,582 |
| Vifor Pharma, Inc. | 201 | $61,231 |
| AstraZeneca | 90 | $52,548 |
| Mallinckrodt Hospital Products Inc. | 62 | $5,150 |
| Amgen(2 entities) | 38 | $1,350 |
| Aurinia Pharma U.S., Inc. | 18 | $707 |
| Otsuka America Pharmaceutical, Inc. | 23 | $617 |
| Travere Therapeutics, Inc. | 12 | $429 |
| GSK | 10 | $395 |
| Mallinckrodt Enterprises LLC | 8 | $389 |
| Novartis | 14 | $336 |
| Lilly USA, LLC | 12 | $314 |
| Ardelyx, Inc. | 9 | $299 |
| Kowa Pharmaceuticals America, Inc. | 10 | $206 |
| Calliditas Therapeutics US Inc. | 8 | $196 |
| Fresenius USA Marketing, Inc. | 10 | $188 |
| Boehringer Ingelheim | 5 | $127 |
| Amarin Pharma, Inc. | 2 | $126 |
| Baxter Healthcare | 1 | $123 |
| OPKO Pharmaceuticals, LLC | 2 | $108 |
| ANI Pharmaceuticals, Inc. | 3 | $108 |
| Novo Nordisk | 5 | $107 |
| Merck | 2 | $42 |
| Siemens Medical Solutions USA, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$402,225 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 1,429 | $1,177,363 |
| VeltassaPatiromer Calcium Sorbitex | 404 | $448,770 |
| KerendiaFinerenone | 483 | $446,233 |
| JardianceEmpagliflozin | 292 | $290,409 |
| JynarqueTolvaptan | 12 | $228,147 |
| VelphoroSucroferric Oxyhydroxide | 62 | $95,429 |
| DapagliflozinDapagliflozin Propanediol | 88 | $41,325 |
| RetacritEpoetin Alfa-Epbx | 42 | $23,123 |
| ProcritEpoetin Alfa | 19 | $21,079 |
| Sevelamer Carbonate | 151 | $20,782 |
| ProsolParenteral Amino Acid 20% No.1 | 81 | $16,156 |
| Bumetanide | 439 | $10,547 |
| VascepaIcosapent Ethyl | 15 | $6,377 |
| Irbesartan | 328 | $4,536 |
| Calcitriol | 96 | $2,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $52,548 | $1,177,3631,429 claims |
| BayerKerendia | $193,435 | $446,233483 claims |
| Boehringer IngelheimJardiance | $127 | $290,409292 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $617 | $228,14712 claims |
| Fresenius USA Marketing, Inc.Velphoro | $188 | $95,42962 claims |
| PfizerRetacrit | $16 | $23,12342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.
Other nephrology in Coral Gables
- Jorge PosadaCoral Gables$2.5M
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.